How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundaci-n-canaria-rafael-clavijo-para-la-investigaci-n-biom-dica.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Fundación Canaria Rafael Clavijo para la Investigación Biomédica — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundación Canaria Rafael Clavijo para la Investigación Biomédica pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IV trivalent saccharose hydroxide ferrous	IV trivalent saccharose hydroxide ferrous	marketed
Macrogol 3350 plus ascorbic acid	Macrogol 3350 plus ascorbic acid	marketed	Osmotic laxative bowel preparation		Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Norgine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Canaria Rafael Clavijo para la Investigación Biomédica:

Cite this brief

Drug Landscape (2026). Fundación Canaria Rafael Clavijo para la Investigación Biomédica — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-canaria-rafael-clavijo-para-la-investigaci-n-biom-dica. Accessed 2026-05-17.